AFICILL: a single-cohort, retrospective study on Atrial Fibrillation In Critically ILL patients admitted to a medical sub-intensive care unit: implications for clinical management, outcomes and elaboration of new data-driven models by Falsetti, Lorenzo
	 1	
Alma Mater Studiorum – Università di Bologna 
 
 
DOTTORATO DI RICERCA IN 
 
SCIENZE CARDIO-NEFRO-TORACICHE 
 
Ciclo 31° 
 
Settore Concorsuale: 06/D1  
 
Settore Scientifico Disciplinare: MED/11 
 
 
 
TITOLO TESI 
 
AFICILL: a single-cohort, retrospective study on Atrial Fibrillation In Critically ILL 
patients admitted to a medical sub-intensive care unit: implications for clinical 
management, outcomes and elaboration of new data-driven models 
 
 
 
 
 
Presentata da: Lorenzo Falsetti 
 
 
 
             Coordinatore Dottorato          Supervisore 
    Prof. Gaetano Domenico Gargiulo       Prof. Francesco Grigioni 
 
            Co-Supervisore 
            Prof. Alessandro Capucci 
 
 
 
 
 
Esame finale anno 2019 
 
	2	
Summary 
• Abstract 
1. Introduction 
a. Atrial fibrillation in the critically-ill patient 
b. Medical population in a subintensive care unit 
c. Current use of big data and machine learning in medicine 
d. Aims of the study 
2. Patients and Methods 
a. Power analysis 
b. Ethics committee approval 
c. Electronic database structure 
d. Definitions 
e. Statistical analysis 
f. Data-driven modelling of new scoring systems 
i. Visualizing multi-dimensional datasets: the t-SNE approach  
ii. Mining insights from multi-dimensional datasets: computational 
topology and Mapper algorithm 
iii. Statistical methods adopted in topological data analysis 
1. Chi-squared test (χ2) 
2. Receiver-operating characteristic (ROC) 
3. Jaccard similarities 
4. Machine learning for data-driven modelling 
3. Results  
4. Discussion 
a. Study limitations 
 
	 3	
Abstract 
Introduction: atrial fibrillation (AF) is common among critically-ill patients, who are 
considered at increased cardioembolic and haemorragic risk. Consequently, anticoagulant 
therapy might be ineffective or harmful for an excess of haemorragic events which could not 
be counterbalanced by an adequate reduction of cardioembolic occurrences.  
Aims: main outcome (MO) was the composite of death or intensive care unit (ICU) transfer 
in a population of critically-ill subjects admitted to a medical subintensive care unit (sICU); 
we assessed (i) thromboembolic events (TEE) and major haemorrhages (MH); (ii) current 
guidelines (GL) adherence and related outcomes; (iii) performance of validated risk scores 
for TEE and MH;  we engineered (iv) new scores adopting machine learning (ML) predicting 
MO, TEE, MH. 
Patients and Methods: single-center, retrospective study enrolling all the consecutive AF-
affected patients admitted to a sICU for critical illness. Demographic, clinical, therapeutic 
and laboratoristic data were collected. Performance of CHA2DS2-VASc and HAS-BLED 
scores was evaluated. GL-adherence and its relationship with outcomes was studied. ML was 
used to engineer new predictive models. 
Results: we enrolled 1430 subjects; CHA2DS2-VASc (AUC:0.516;95%CI:0.472-0.560) and 
HAS-BLED (AUC:0.493;95%CI:0.443-0.543) did not predict TEE or MH; in-hospital 
warfarin use was associated to increased MO risk (OR:1.73;95%CI:1.06-2.83; p<0.05); low-
molecular-weight-heparin use was not associated to an increased MO risk; antiplatelet drugs 
use was associated to MO risk reduction (OR:0.51;95%CI:0.34-0.78;p<0.002). GL-adherent 
treatment was associated to TEE risk reduction and MH and MO risk increase; ML identified 
specific features for MO, TEE, MH: ML-based classifiers outperformed CHA2DS2-VASc 
(AUC: from 0.516 to 0.90, p<0.0001) and HAS-BLED (AUC: from 0.493 to 0.82, p<0.0001). 
Discussion: AF-related outcomes cannot be predicted in critically-ill patients with currently 
validated methods. GL-adherence is associated to a significant TEE reduction, but also to 
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MH and MO increase. ML algorithms can identify the most important features and shape 
specific scores able to outperform the classical models. 
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1. Introduction 
Atrial fibrillation in the critically-ill patient 
Atrial fibrillation (AF) is the most common sustained arrhythmia observed both in 
general population[1] and in several groups of hospitalized patients[2]. Among critically-ill 
subjects admitted in intensive care units (ICU), pre-existing and new-onset forms of AF can 
be observed in 1 out of 3 admitted patients[3].  
New-onset AF has a prevalence ranging between 5 and 46%[4] and represents 47.4-
61% of all the arrhythmias and 52% of the atrial arrhythmias observed in ICU[2,5,6]. Pre-
existing AF follows the same prevalence of the general population[7], and is present in 9% of 
the patients admitted to ICU for critical illness[8]. Moreover, pre-existing AF has a better-
known pathophysiology: it is strongly linked to ageing[9,10] and its associated comorbidities, 
as chronic heart failure (CHF), diabetes, valvular diseases, acute coronary syndromes (ACS) 
and hypertension (HYP)[11]. These disorders favour atrial structural and electrical 
remodelling, offering an ideal arrhythmogenic substrate[12]. Several factors, as electrolytic 
and volume disturbances, sympathetic and parasympathetic activity alterations are common 
AF triggers. The association of a substrate and a trigger is able to initiate and maintain 
AF[12,13].  
 The classical risk factors and triggers, however, show a weaker association with AF 
when it occurs during a critical illness[14], and other features seem to be implied in 
triggering and maintaining new-onset AF[4]. Acute pathologies, presence of organ failure 
and the activation of the inflammatory systemic response are supposed to induce atrial 
structural and electric remodelling[3,14,15]. Beta-agonist and vasopressor drugs, sustained 
tachycardia, bacterial toxins, neuro-hormonal and electrolyte disturbances, myocardial 
ischemia and volume overload can trigger a new-onset AF[3,4]. Moreover, proinflammatory 
cytokines have a direct arrhythmogenic effect of on atrial myocardium[16].  
 Acute occurrence of AF in the setting of a critical illness is often associated to a 
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deterioration of global haemodynamic due to fast and irregular ventricular response rate and 
to the loss of atrial systole[3,17], but also to an increased risk of stroke[18], acute heart 
failure (AHF)[19], and death[3].  
 Several authors showed that AF increased the risk of in-hospital mortality in specific 
pathologies, as in sepsis[20], trauma[21], ACS[22,23] and AHF[24], but also in generic 
cohorts of critically-ill patients admitted both in medical[25] and surgical[26] ICU. In the 
long-term, these patients had a greater risk of rehospitalisation for AHF and stroke and an 
increased risk of death, which remained high up to 5 years after hospital discharge[27]. 
 Previous reports underlined the association between poorer clinical outcomes and 
new-onset AF[14]. However, new-onset AF did not always result independently predictive 
for in-hospital mortality after adjusting for disease severity, suggesting that this type of AF 
could be a marker of prognosis rather than an independent risk factor[28,29]. Pre-existing AF 
has been identified as an independent risk factor for in-hospital mortality and worse 
functional outcomes in ACS, AHF[22,30,31] and in generic ICU populations[8]. 
 Despite the epidemiologic and prognostic relevance of the problem, the clinical 
management of AF during a critical illness is still object of debate. Currently, studies 
underline no benefit of a rhythm control over a rate control strategy in the critically-ill 
patient, and do not allow to generate any recommendation for a standard treatment[32], 
except for the cases of cardiogenic shock due to elevated cardiac frequency, where urgent 
electric cardioversion is mandatory[1]. Medications adopted for both rate and rhythm control 
are poorly evaluated in the setting of a critical illness and several studies underlined a 
significant practice variability in the prescription of different rate-control drugs[3]. Even the 
correct dose of commonly used medications, as amiodarone or magnesium sulphate, is 
currently under investigation in the specific clinical setting of ICU and in severe sepsis 
(clinicaltrials.gov ID NCT01049464; clinicaltrials.gov ID: NCT02668432). 
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 Critical illness itself represents a procoagulant state, and the coexistence of AF 
implies a markedly increased thromboembolic risk[33]. This increased risk has been 
demonstrated for new-onset AF in severe sepsis[18], ACS[34], AHF[35] and acute 
respiratory failure (ARF)[36]. Similarly, pre-existing AF has been associated to an increased 
stroke risk in ICU patients[8]. Anticoagulation in this subset of patients, however, has not 
been related to a significant reduction of stroke risk, but to a significant increase of bleeding 
risk[36,37].  
 The accuracy of the currently adopted clinical prediction scores in critically-ill 
subjects is still object of debate: while some authors recommend the use of CHA2DS2-VASc 
score at a different cutoff to stratify the thromboembolic risk in the critically-ill patients[38], 
others underline its low predictive value[36,39] and emphasise the presence of a very high 
haemorragic risk which cannot be accurately quantified by HAS-BLED score[36,40]. 
Medical population of a semi-intensive care unit 
The number of critically-ill patients (and their comorbidities) is increasing along with 
ageing of the population. In order to reduce ICU overcrowding and optimize resources, this 
subset of patients is often managed in specific Internal Medicine departments, named semi-
intensive care units, or sICU. The sICU population usually differs from ICU for a more 
advanced age of patients but also for an increased number of comorbidities as chronic 
respiratory failure, chronic kidney disease, dementia, CHF and cancer, with a worse 
prognostic profile and an even higher AF prevalence due to age and associated pathologies. 
Current use of big data and machine learning in medicine 
Medical informations are now collected continuously at the bedside: demographic data, 
clinical informations, pharmacological therapy, physiological signs, laboratory analysis and 
radiologic data can now be easily collected, stored and analysed. Thus, a big data repository 
is usually defined by five “Vs”: volume (large quantity of data), velocity (high speed of 
acquisition), variety (difference of the data sources), veracity (uncertainty of data quality) and 
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value (possible valorisation of the data)[41]. Both ICU and sICU, for their technological 
implementation, represent the ideal environment where to collect and analyse this type of 
informations.  
Due to its multidimensionality, big data analysis cannot be adequately performed with the 
classical statistical methods: several machine learning (ML) techniques are currently used to 
explore hidden relationships between different variables. This process is done automatically, 
but a human supervision is often necessary to clarify the results and avoid spurious 
interpretations.  
Techniques based on a specific set of algorithms, named topological data analysis 
(TDA), are commonly used to explain relationships between variables in large datasets, 
especially in critical bio-medical and medical phenomena. TDA has been successfully 
applied in medical studies regarding cancer[42], simulated human immune systems 
dynamics[43] and pulmonary embolism (PE)[44]. In the setting of TDA, our group already 
used an hypernetwork approach and Q-analysis to identify informative medical features and 
instruct an artificial neural network to predict automatically the pretest probability of PE[44]. 
Hypernetworks provide a significant generalization of network theory, enabling the 
integration of relational structure, logic and analytic dynamics. With this novel approach, the 
resulting neural hypernetwork correctly recognized 94% of the patients affected by PE before 
the CT-scan. In other studies in the same dataset, we identified key features which were best 
associated to PE diagnosis[45,46] to engineer a ML algorithm which was able to outperform 
the classical methods, represented by Wells and Geneve scores.  
Aims of the study 
Objective of Atrial Fibrillation In Critically ILL (AFICILL) study was to evaluate the 
occurrence of the main outcome (MO), defined as death or ICU transfer, in a single-cohort, 
retrospective study of critically-ill patients affected by AF and admitted to a medical sICU. 
We also aimed to: 
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• evaluate	 risk	 factors,	 comorbidities	 and	 concurrent	 clinical	 events	 significantly	and	independently	associated	to	MO;	
• assess	 the	 prevalence	 of	 cardioembolic	 events	 (TEE)	 and	 major	 haemorrhage	(MH)	as	main	clinical	adverse	events	associated	to	AF	in	this	setting;	
• appraise	 the	 association	 and	 the	 predictive	 capacity	 of	 CHA2DS2-VASc	 for	 TEE	and	HAS-BLED	for	MH	in	this	cohort;	
• estimate	the	adherence	to	the	indications	of	the	European	Society	of	Cardiology	(ESC)	 AF	 guidelines[1]	 for	 anticoagulant	 therapy	 and	 assess	 the	 association	between	guidelines	adherence	(GL)	and	adverse	clinical	events;	
• identify	 risk	 factors	 for	 MO,	 TEE	 and	 MH	 in	 this	 population	 of	 patients	 and	generate	new	predictive	models	adopting	a	TDA-based,	ML	algorithm.	
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2. Patients and Methods 
Study cohort and baseline characteristics 
 In order to evaluate the study objectives, we retrospectively analyzed a cohort of 
critically-ill patients with AF admitted to the internal and sub-intensive medicine department 
of the Azienda Ospedaliero-Universitaria “Ospedali Riuniti” in Ancona, Italy. Since January 
01st 2002 the department adopted an electronic medical record (eMR) system for inpatients’ 
management, that allows to interrogate the main database to select patients characterized by a 
specific diagnosis. All diagnoses in the eMR are coded according to ICD-9 system. In the aim 
of the study, we selected all patients admitted to the sICU with a concurrent diagnosis of AF 
(ICD-9: 427.31) from inception to 31/03/2018, then we randomly decided “a priori” to select 
the first consecutive 25% of the entire AF cohort to include in the study, in order to keep the 
data collection timely and effective. Afterward, we excluded all patients admitted performing 
a planned cardioversion procedure for AF rhythm control, stable patients without acute organ 
failure and patients admitted for trauma or surgical pathologies in order to keep only the 
medical, critically-ill patients. We then obtained from the eMR and from the detailed 
examination of discharge reports all the data regarding demographics, history of risk factors 
and comorbidities, admission diagnoses, concurrent clinical events and use of antithrombotic 
drugs. 
Power Analysis 
 According to literature, mortality due to critical illness in ICU is estimated at 15% of 
the population. Setting a priori an alfa of 0.050 in a two-tailed test, we estimated that a 
sample size of 1430 patients was able to establish this outcome with a precision of ±2% 
(95%CI). 
Ethics Committee Approval 
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 The local ethics committee (CERM, Comitato Etico Regione Marche, Azienda 
Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, Italy) reviewed the protocol and 
approved the study (protocol number: 2018/168, 21/06/2018, see Appendix 1). 
Electronic Database Structure 
 The database structure, the format of the collected variables, their content, their names 
and abbreviations are synthesized in Table 1. We collected the unique identifier, the number 
of admissions and the patient’s age at the admission as continuous variables. Main outcome, 
sex, electric cardioversion (CVE), pharmacologic cardioversion (CVF), the reason of sUTI 
admission (syncope, trauma, acute coronary syndrome, acute heart failure, cardiogenic shock, 
haemorragic shock, septic shock, acute kidney injury and acute respiratory failure), 
comorbidities (chronic heart failure, chronic obstructive lung disease, peripheral artery 
disease, previous stroke/TIA, chronic hepatic pathology, chronic kidney disease, chronic 
ischemic cardiopathy, diabetes mellitus, chronic anaemia, hypertension, active cancer, 
alcohol abuse, mitral valve disease and aortic valve disease), previous gastrointestinal (GI) 
bleeding, low time in therapeutic range (TTR), acetylsalicylic acid/clopidogrel use were 
categorized as binary variables.  
 Type of AF, type of MH, type of TEE, anticoagulant therapy at admission, 
anticoagulant therapy at discharge, acute neurologic syndromes, infections and the number of 
comorbidities were collected as categorical variables.  
 
Table 1: Database structure and type of collected variables 
Variable Name Content Format 
DATE Date of admission dd/mm/yyyy 
ID Unique identifier continuous 
ADM Number of admissions  continuous 
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SEX Patient’s sex binary 
AGE Patient’s age at the admission continuous 
MO In-hospital death or ICU transfer 
0: Discharged  
1: Death in sUTI 
1: UTI transfer 
binary 
AF_TYPE Atrial fibrillation type 
1: Paroxysmal 
2: Persistent 
3: Permanent 
categorial 
MH_TYPE Major haemorrhage type 
1: ICH/ESA 
2: Gastrointestinal bleeding 
3: Urinary tract bleeding  
4: Intramuscular bleeding 
5: Other 
categorial 
TEE_TYPE Cardioembolic event type 
1: Stroke/TIA 
2: Atrial appendage thrombus 
3: Systemic embolization  
4: Lower limb ischemia (embolic)  
categorial 
CVE Electric cardioversion binary 
CVF Pharmacologic cardioversion binary 
AC_ING Anticoagulant therapy at admission categorial 
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0: Warfarin 
1: LMWH 
3: No Anticoagulant 
AC_DISMISS Anticoagulant therapy at discharge 
0: Warfarin 
1: LMWH 
3: No Anticoagulant 
categorial 
Critical Illnesses at sICU admission 
SYN Syncope binary 
AC_NEUR Acute neurologic syndromes binary 
TRAUMA Trauma  binary 
ACS Acute coronary syndromes binary 
AHF Acute heart failure binary 
CS Cardiogenic shock binary 
HS Haemorragic shock binary 
SS Septic shock binary 
AKI Acute kidney injury binary 
ARF Acute respiratory failure binary 
INF Infection 
1: Pneumonia 
2: Abdominal infections 
3: Urinary tract infections 
4: Other 
categorial 
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Comorbidities 
CHF Chronic heart failure binary 
COPD Chronic obstructive lung disease binary 
PAD Peripheral artery disease binary 
STROKE_TIA Previous stroke or TIA binary 
CHP Chronic hepatic pathologies binary 
CKD Chronic kidney disease binary 
CCS Chronic ischemic cardiopathy binary 
T2DM Type 2 diabetes mellitus binary 
CA Chronic anaemia binary 
PREVIOUS_BLEED Previous gastrointestinal bleeding binary 
HYP Hypertension binary 
AC Active cancer binary 
COMORBIDITIES Number of comorbidities categorial 
LOW_TTR Low time in therapeutic range binary 
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ASA_CLOP Acetylsalicylic acid or Clopidogrel use binary 
ALC_ABUSE Chronic alcohol abuse binary 
MV_PAT Mitral Valve Disease binary 
AO_PAT Aortic valve disease binary 
CHA2DS2-VASc CHA2DS2-VASc Score categorial 
HASBLED HAS-BLED Score categorial 
CHADS2 CHADS2 Score categorial 
Legend: ICU=intensive-care unit; sICU= subintensive-care unit; ICH= intracranial 
hemorrhage; ESA= subarachnoid hemorrhage; TIA= transient ischemic attack; LMWH= low 
molecular weight heparin. 
 
We calculated CHADS2, CHA2DS2-VASc and HAS-BLED score following their 
original definitions [47–49], as shown in Table 2 and Table 3 and collected these scores as 
categorical variables. 
 
Table 2: CHADS2 and CHA2DS2-VASc score 
CHADS2 Score 
Item Meaning Score 
C CHF History +1 
H Hypertension History +1 
	16	
A Age >75 +1 
D Diabetes Mellitus +1 
S2 Previous Stroke / TIA / Thromboembolism +2 
CHA2DS2-VASc Score 
Item Meaning Score 
C CHF History +1 
H Hypertension History +1 
A2 Age: >75 +2 
D Diabetes Mellitus +1 
S2 Previous Stroke / TIA / Thromboembolism +2 
V Vascular disease History +1 
A Age: 65-74 +1 
Sc Sex Category (i.e. Female Sex) + 1 
Legend: CHF= chronic heart failure; TIA= transient ischemic attack. 
 
Table 3: HAS-BLED score 
Item Meaning Score 
H Hypertension +1 
A Age > 65 +1 
S Stroke History +1 
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 Labile INR (TTR < 60%) +1 
B Prior Major Bleeding or Predisposition +1 
L Liver Disease +1 
 Renal Disease +1 
E Alcohol Use +1 
D Drugs (ASA, NSAIDS) +1 
Legend: INR= international normalized ratio; TTR= time in therapeutic range; ASA= acetyl 
salicylic acid; NSAIDS= non-steroidal anti-inflammatory drugs. 
 
Last, we subdivided the overall sample according to GL-adherence. For patients 
without ACS we considered the indications in the 2016 ESC guidelines on AF[1]. For 
patients admitted with ACS, we also considered the indications in latest ESC GL on 
ACS[50,51]. Patients were divided into GL-adherent, overtreated or undertreated according 
their admission diagnosis and therapy, as shown in Figure 1. 
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Figure 1: Subdivision of the sample according to current GL adherence 
Legend: NT= no treatment; AP= antiplatelet therapy; AC= anticoagulant therapy; AP+AC= 
antiplatelet and anticoagulant therapy; GL= guidelines 
 
Definitions 
• critically-ill	 patient:	 we	 defined	 as	 “critically-ill”	 all	 the	 subjects	 who	 –	 at	 the	admission	–	had	one	or	more	medical	conditions	at	high	risk	of	death,	following	the	 MeSH	 definition,	 and	 who	 were	 admitted	 with	 at	 least	 one	 acute	 organ	dysfunction.	
• main	 outcome	 (MO):	 we	 intended	 to	 evaluate	 the	 rate	 of	 therapeutic	 failure,	defined	as	in-hospital	mortality	or	ICU	transfer.			
• major	 bleeding	 (MH):	 we	 collected	 all	 the	 major	 haemorragic	 events	 defined	according	ISTH	definition	of	MH	in	non-surgical	patients[52],	intended	as	(i)	fatal	bleeding,	 and/or	 (ii)	 symptomatic	 bleeding	 in	 a	 critical	 area	 or	 organ	(intracranial,	 intraspinal,	 intraocular,	 retroperitoneal,	 intra‐articular	 or	pericardial,	 or	 intramuscular	 with	 compartment	 syndrome),	 and/or	 (iii)	
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bleeding	causing	a	fall	in	haemoglobin	level	≥	20	g/L,	or	leading	to	transfusion	of	≥	 2	 units	 of	 whole	 blood	 or	 red	 cells.	 Particularly,	 we	 classified	 MH	 into	 the	following	subclasses:	
o intracranial	haemorrhage	(ICH)	or	subarachnoid	haemorrhage	(ESA)		
o gastrointestinal	bleeding	
o urinary	tract	bleeding	
o intramuscular	or	retroperitoneal	bleeding	
o other	sites	
• thromboembolic	 event	 (TEE):	 we	 recorded	 all	 the	 ischemic	 events	 with	 a	presumable	 cardioembolic	 source	 during	 AF	 as	 stroke,	 TIA	 or	 systemic	embolization.		
o stroke/TIA:	 we	 enrolled	 all	 subjects	 with	 stroke	 or	 transient	 ischemic	attack	(TIA)	where	AF	was	 the	most	probable	source	of	embolism,	after	evaluating	all	other	causes	of	non-AF	cardioembolic	stroke[53].	
o atrial	 appendage	 thrombus:	 enrolled	 subjects	 undergoing	 to	 urgent	electric	 or	 pharmacologic	 cardioversion	 were	 submitted	 to	 trans-oesophageal	echocardiography,	and	the	presence	of	thrombi	in	the	atrial	appendages	was	recorded.	
o embolic	 limb	 ischemia:	 acute	 ischemia	 of	 embolic	 origin	 appearing	 in	lower	or	upper	limbs.	
o systemic	embolization:	presence	of	synchronous	embolization	in	multiple	sites	(visceral,	limb	and	cerebral).	
• atrial	 fibrillation	 (AF):	 	 all	 patients	 underwent	 electrocardiogram	 at	 the	admission	in	our	sICU;	we	admitted	all	patients	showing	the	typical	AF	pattern,	as	 defined	 by	 ESC	 Guidelines	 2016:	 “absolutely	 irregular	 RR	 intervals	 and	 no	
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discernible,	distinct	P	waves”[1].	We	excluded	from	the	study	all	the	cases	where	the	cause	of	 the	arrhythmia	was	deemed	to	be	associated	 to	a	valvular	disease	(such	as	mechanic	valves	or	severe	mitral	disease).	We	deemed	as	diagnostic	the	documented	 episodes	 lasting	 at	 least	 30	 seconds.	According	 to	 clinical	 history,	we	classified	AF	into	three	subclasses[1]:	
o 	paroxysmal:	 events	 self-terminating	within	 48	hours	 after	 admission	 or	cardioverted	within	7	days	from	onset.	
o persistent:	 events	 lasting	more	 than	7	days	or	undergoing	cardioversion	after	7	or	more	days.	
o permanent:	 events	 in	which	 a	 rate-control	 approach	was	 preferred	 to	 a	rhythm-control	approach.	
• electrical	 cardioversion	 (CVE),	 pharmacologic	 cardioversion	 (CVF):	 patients	who	were	selected	for	rhythm-control	strategies	underwent	to	CVE	or	CVF,	according	current	guidelines[1].	A	treatment	strategy,	drug	or	procedure	was	not	preferred	over	another.		
• anticoagulant	 therapy	 at	 admission	 (ADM),	 anticoagulant	 therapy	 at	 discharge	
(DIS):	 we	 recorded	 all	 the	 anticoagulant	 therapies	 at	 admission	 and	 at	 the	discharge	of	each	subject.	Direct	oral	anticoagulants	(DOACs)	were	not	available	at	the	time	of	the	study.	Particularly,	we	evaluated	the	use	of:	
o warfarin	
o low	molecular	weight	heparin	(LMWH)	
o 	no	anticoagulant	therapy	
• reason	 of	 admission	 in	 sICU:	 the	 acute	 pathology	 for	 sICU	 admission	 was	synthesized	 and	 collected.	 Of	 note,	 more	 than	 one	 acute	 pathology	 could	 be	present	in	the	same	patient.	Particularly,	we	assessed:	
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o syncope	 (SYN):	 patients	 assessed	 for	 transient	 loss	 of	 consciousness	 in	whom	a	definite	diagnosis	of	cardiogenic	cause	was	ascertained	according	to	 the	2009	ESC	guidelines	on	management	of	 syncope[54],	which	were	adopted	at	the	time	of	the	study.	
o acute	 neurological	 syndromes	 (ANS):	 subjects	 admitted	 for	 status	epilepticus	 or	 other	 life-threatening	 neurological	 pathologies,	 except	stroke/TIA,	which	was	recorded	as	part	of	TEE.	
o trauma:	patients	admitted	for	major	head	trauma,	blunt	or	open	thoracic	trauma,	blunt	or	open	abdominal	trauma	were	gathered.	
o acute	coronary	syndrome	(ACS):	ST-elevated	or	non-ST	elevated	ACS	were	diagnosed	according	current	guidelines[50,51]	and	classified	according	to	the	third	universal	definition	of	myocardial	infarction[55].	
o acute	 heart	 failure	 (AHF)	 was	 defined	 and	 diagnosed	 according	 current	ESC	guidelines[56]	as	a	rapid	onset	or	worsening	of	typical	symptoms,	as	breathlessness,	 ankle	 swelling	 and	 fatigue,	 accompanied	 by	 signs,	 as	elevated	 jugular	 venous	 pressure,	 pulmonary	 crackles	 and	 peripheral	oedema[56].	
o shock:	 was	 defined	 as	 a	 failure	 to	 perfuse	 or	 oxygenate	 vital	 organs,	according	MeSH	definition,	and	was	subdivided,	upon	the	aetiology,	into:		
§ cardiogenic	 shock	 (CS)	 was	 identified	 as	 a	 state	 of	 end-organ	hypoperfusion	due	to	cardiac	failure[57].	
§ haemorragic	 shock	 (HS)	was	 defined	 as	 a	 form	 of	 hypovolemic	shock	 in	 which	 severe	 blood	 loss	 leads	 to	 inadequate	 oxygen	delivery	at	the	cellular	level[58].	
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§ septic	 shock	 (SS)	 was	 diagnosed	 according	 to	 2001	SCCM/ESICM/ACCP/ATS/SIS	 International	 Sepsis	 Definitions	Conference	definition[59].	
o acute	 kidney	 injury	 (AKI)	 was	 diagnosed,	 adopting	 the	 modified	 RIFLE	criteria,	as	a	serum	creatinine	increase	≥	0.3	mg/dl	occurring	within	a	48-hour	period[60].	
o acute	respiratory	failure	(ARF):	was	defined	as	the	acute	inadequacy	of	the	lungs	 to	 maintain	 either	 acceptable	 blood	 oxygenation,	 or	 to	 allow	 a	normal	arterial	blood	carbon	dioxide	 levels	or	both[61]	and	categorized	in	type	1	(hypoxemic)	or	type	2	(hypercapnic).	
o infection	 (INF)	 was	 defined	 by	 the	 clinical,	 radiologic	 and	 cultural	detection	of	an	infection	in	a	specific	organ,	and	was	subdivided	into:	
§ thoracic	infections	(pneumonia,	mediastinitis)	
§ non-surgical	 abdominal	 infections	 (appendicitis,	 cholecystitis,	
diverticulitis,	peritonitis)	
§ symptomatic	urinary	tract	infections	
§ other	
• comorbidities:	 we	 also	 investigated	 the	 presence	 of	 one	 or	 more	 associated	chronic	pathologies	in	each	enrolled	patient.	
o chronic	 heart	 failure	 (CHF)	 was	 diagnosed	 according	 current	guidelines[56]	 and	 defined	 as	 “a	 clinical	 syndrome	 characterized	 by	typical	 symptoms	 (e.g.	 breathlessness,	 ankle	 swelling	 and	 fatigue)	 that	may	 be	 accompanied	 by	 signs	 (e.g.	 elevated	 jugular	 venous	 pressure,	pulmonary	 crackles	 and	 peripheral	 oedema)	 caused	 by	 a	 structural	
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and/or	 functional	 cardiac	 abnormality,	 resulting	 in	 a	 reduced	 cardiac	output	and/or	elevated	intracardiac	pressures	at	rest	or	during	stress”.	
o chronic	obstructive	lung	disease	(COPD)	was	diagnosed	according	current	guidelines[62]	 and	 defined	 as	 persistent	 respiratory	 symptoms	 and	airflow	limitation	due	to	airway	and/or	alveolar	abnormalities.	
o peripheral	artery	disease	 (PAD)	 was	 diagnosed	 by	 physical	 examination,	history	 and	 echo-colour	 doppler	 and	 defined	 as	 a	 chronic	 tissue	hypoperfusion	 due	 to	 atherosclerosis	 of	 extracranial	 carotid	 and	vertebral,	mesenteric,	renal,	upper	and	lower	extremity	arteries[63].	
o previous	stroke/TIA:	was	defined	as	a	history	of	stroke	or	TIA.	
o chronic	 hepatic	 pathologies	 (CHP)	 were	 defined	 as	 the	 presence	 of	cirrhosis	 of	 any	 cause	 or	 chronic	 infection	 by	 HBV,	 HCV	 or	 other	hepatotropic	viruses.		
o chronic	kidney	disease	(CKD)	was	defined	as	kidney	damage	or	glomerular	filtration	 rate	 (GFR)	 <60	 mL/min/1.73	 m2	 for	 3	 months	 or	 more,	irrespective	 of	 cause[64].	 eGFR	 was	 estimated	 with	 Cockroft-Gault	formula.	
o chronic	ischemic	cardiopathy	(CCS)	was	diagnosed	in	presence	of	a	history	of	myocardial	infarction	or	chest	discomfort	(angina	pectoris)[65].	
o type	2	diabetes	mellitus	(T2DM)	was	diagnosed	in	presence	of	a	history	of	T2DM	and/or	anti-diabetic	therapies	at	the	admission.	
o chronic	 anaemia	 (CA)	 was	 diagnosed	 when	 a	 chronic	 reduction	 of	haemoglobin	below	13.7	g/dl	in	men	and	below	12.2	g/dl	in	women[66].	
o previous	gastrointestinal	(GI)	bleeding:	was	defined	as	a	history	of	upper	or	lower	GI	bleeding	confirmed	by	appropriate	endoscopic	studies.	
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o hypertension	 (HYP)	 was	 identified	 in	 presence	 of	 a	 history	 of	 poorly	controlled	 hypertension	 and/or	 anti-hypertensive	 therapy	 use	 at	 the	admission	 with	 an	 history	 of	 poor	 blood	 pressure	 control.	 Due	 to	 the	frequent	 alterations	of	 blood	pressure	 values	 in	 the	 critically-ill	 patient,	we	did	not	consider	the	blood	pressure	values	during	hospitalization	for	diagnostic	purposes.	
o active	 cancer	 (AC)	 was	 diagnosed	 in	 presence	 of	 history,	 physical	examination	and	laboratoristic/instrumental	exams	suggestive	for	active	cancer	at	the	admission	of	the	patient.	
o low	time	in	therapeutic	range	(TTR)	 the	quality	of	 anticoagulation	 in	 the	12	months	preceding	 the	hospitalization	 in	patients	anticoagulated	with	warfarin	 was	 evaluated	 with	 TTR,	 calculated	 with	 the	 Rosendaal	method[67]:	TTR	was	defined	labile	for	values	<	60%,	as	required	by	the	HAS-BLED	score.	
o use	 of	 acetylsalicylic	 acid	 or	 clopidogrel	 (ASA_CLOP)	was	 defined	 by	 the	use,	 at	 the	 time	of	admission,	of	acetylsalicylic	acid,	 clopidogrel	or	other	antiplatelet	drugs.	
o alcohol	abuse	(ALC)	was	defined	as	chronic	abuse	of	alcoholic	substances.	
o mitral	valve	disease	(MVP)	or	aortic	valve	disease	(AVP):	were	diagnosed	if	at	 echocardiogram	 were	 present	 mitral	 valve	 stenosis	 and/or	insufficiency	 and/or	 aortic	 valve	 stenosis	 and/or	 insufficiency.	 We	excluded	from	the	present	study	all	the	patients	in	whom	the	cause	of	AF	was	attributable	to	the	valvular	pathology.	
Statistical analysis 
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 Continuous variables were reported as mean and standard deviation (SD) or median 
and interquartile range (IQR), according to a normal or non-normal distribution of values. 
The statistical difference between subgroups has been evaluated, respectively, with t-test (2 
groups, normal distribution), ANOVA test (more than 2 groups) or with Mann-Whitney U 
test (2 groups, non-normal distribution) and Kruskal-Wallis ANOVA test (more than two 
groups). Categorial variables were reported as number of subjects and their proportion. 
Differences between subgroups have been evaluated with χ2 test. 
 The association of the clinical factors with the main outcome was evaluated with 
logistic regression analysis. Demographic and clinical variables was assessed first with 
univariate analysis: all the variables associated with the main outcome with a p value equal or 
less than 0.010 were included in the multivariate analysis.  The association between risk 
scores and adverse clinical events was assessed with a logistic regression model developed 
with the same methodology adopted to study the relationship between clinical factors and the 
main outcome. 
 Predictivity of risk scores was evaluated adopting the c-statistics. We calculated also 
sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive 
value (NPV) adopting the standard cut-offs. Receiver-operator curves (ROC) were calculated 
in 2D graphs considering the true positive rate (Se) in the y-axis and the true negative rate (1-
Sp) in the x-axis. For each curve, the area under the curve (AUC) was calculated. Differences 
between curves were calculated accordingly to DeLong method[68]. 
We considered as statistically significant a p-value less or equal to 0.05 for two-tailed 
tests. Statistical analysis has been performed with SPSS 25.0 and Microsoft Excel for Mac 
OSx. 
Data-driven modelling of new scoring systems 
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 Visualizing multi-dimensional datasets: the t-SNE approach. The dataset under 
examination described each patient with 45 categorical and numerical variables synthesizing 
different clinical aspects of the enrolled patients.  
Because of this high dimensionality, the dataset could not be immediately visualized 
by human brain, which is capable to shape only data belonging to 3 dimensions. A first 
attempt to visualize the dataset could be of producing a huge amount of 3d scatter plots made 
by plotting 3 variables at time. This brute-force approach, however, is able to discern only a 
few and incomplete set of insights. Thus, is important to instruct a more complex but suitable 
approach for dataset visualization.  
Literature suggests different techniques for visualizing high dimensional datasets: for 
a complete review we referred to [69]. Among these, t-Distributed Stochastic Neighbour 
Embedding (t-SNE) is one of the mostly used techniques, which is able to visualize datasets 
up to 50 dimensions. t-SNE is defined as a “non-linear dimensionality reduction algorithm”, 
which finds patterns in the data by identifying observed clusters based on similarity of data 
points with multiple features. It is important to underline the concept that t-SNE is not a 
clustering algorithm, but a “dimensionality reduction algorithm”, which maps the multi-
dimensional data to a lower dimensional space, where the input features are no longer 
identifiable. Thus, it is not possible to make any inference using t-SNE output only which is 
conceptually a data exploration and visualization technique. t-SNE maps multi-dimensional 
data to two or more dimensions, making it suitable for human observation. The algorithm for 
computing t-SNE considers 4 main steps. Step 1 and Step 2 calculate the conditional 
probability of similarity between a pair of points in high dimensional space and then in low 
dimensional space. In Step 3 and Step 4 t-SNE tries to minimize the sum of the difference in 
conditional probabilities and the algorithm finds the best parameters for retaining the local 
structure of the data in the map. This algorithm optimizes the search of the “hyper-parameter” 
in regard to the so-called perplexity. Perplexity is inputted by the user: this value can be 
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interpreted as a smooth measure of the effective number of neighbours. Typical values are 
between 5 and 50. For a complete technical overview of this methodology we refer to 
[70,71]. In Table 4 we report a comparison by using different perplexity values on the same 
dataset[72].  
Medical studies often use principal component analysis (PCA), which is a long-
standing technique for data visualization and reduction. However, PCA has some limitations: 
it is a linear algorithm, and it will not be able to interpret complex non-linear relationship 
between features. A major problem with linear dimensionality reduction algorithms is that 
they concentrate on placing dissimilar data points far apart in a lower dimension 
representation. However, in order to represent high dimensional data on lower dimensions it 
is important that similar data points must be represented close together, which is not what 
linear dimensionality reduction algorithms do. For a complete technical review of t-SNE we 
refer to [73]. 
 
Table 4: example of t-SNE: visualization of cell types in the mouse cortex and hippocampus. 
 
 Mining insights from multi-dimensional datasets: computational topology and 
Mapper algorithm: t-SNE retains both the local and global structure of the data at the same 
  
Perplexity 30: classes are well grouped except for the endothelial Perplexity 50: the endothelial is now more grouped 
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time but it does not care of the meta-scale proximities among data. Meta-scale is the 
dimension between micro and macro. Topology is the branch of mathematics that aims to 
study the shapes and the maps among them. A topological space is an abstract space 
equipped with some notions of similarities.  There are several ways for building a topological 
space, we are interested to the ones obtained by using the so-called simplicial complex.  
Simplicial complex is the most suitable construction of topological space even they 
are combinatorial objects that can be easily constructed and studied by software systems. An 
abstract simplicial complex is the subset of the power set of a vertex set. For example, given 
the vertex set V = {0,1,2}, the power set 2V of V is 2V 
={{∅},{0},{1},{2},{0,1},{0,2},{1,2},{0,1,2}}, and one simplicial complex can be {0,1,2}.  
Instead of dealing with an abstract simplicial complex, the researcher could be 
interested in geometrical construction: a simplicial complex is obtained by nesting together 
small pieces, known as simplices. The most common simplices are labelled as follows: 0-
simplex is represented by a vertex, 1-simplex is represented by an edge, 2-simplex is 
represented by a filled triangle, 3-simplex is represented by a filled tetrahedron. During the 
construction of the final simplicial complex only a constrain must be respected: the 
intersection between two simplices must be the empty set or must be proper, meaning that 
they must share all their simplices or at least one simplices of dimension less the dimension 
of the whole simplices. A new set of algorithms for the construction of simplicial complexes 
and their analysis has been derived from algebraic topology and they are known as 
topological data analysis. TDA is sensitive to both large- and small-scale patterns that often 
fail to be detected by other analysis methods, such as principal component analysis, (PCA), 
multidimensional scaling, (MDS), and cluster analysis.  
This technique is able to explore and synthesize the relationships between large sets of 
data and is nowadays largely used for exploratory data mining in big data studies. An 
example of TDA workflow is shown in Figure 3.  
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Figure 3: (A) a 3D object (hand) is represented as a point cloud. (B) a filter value is applied 
to the point cloud and the object is now coloured by the values of the filter function. (C) the 
data set is binned into overlapping groups. (D) each bin is clustered and a network is built. 
Picture and caption from [74].  
  
 
TDA can be derived in three main classes of algorithms: persistent homology, 
hypernetwork and mapper.  Homology is an algebraic machinery that counts the number of 
holes in a simplicial complex. Persistent homology is the computational implementation of 
homology. Persistent homology builds simplicial complexes from data in an iterative fashion. 
If the input dataset is a point cloud data, a Vietoris-Rips algorithm or equivalent is used to 
build the simplicial complex. While, if the input dataset is a network then the completion to a 
simplicial complex is obtained by clique weight rank persistent homology. Once the 
simplicial complex is obtained its homology is studied. Persistent homology takes as input 
the list of simplices within a simplicial complex and iterates over. At each iteration simplicies 
are added to the topological space and the number of n-dimensional holes is computed. Holes 
that are found at the end of the process are labelled as persistent, the other are classified as 
noise.  
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Mapper builds a 1-dimensional simplicial complex from data. A 1-dimensional 
simplicial complex is obtained connecting together vertices (nodes) with edges. This 
structure coincides with a graph. A graph G is a set of nodes V and a set of edges E: G=(V,E)  
where E⊆VxV. Before recalling the technical details of the Mapper algorithm, we provide an 
example in Figure 4. 
 
Figure 4: An example of Mapper with artificially generated 2D point cloud data  
 
 
The example in Figure 4 shows Mapper output from an artificially-generated point cloud 
data. The data in the example consists of 5000 points randomly generated from a Gaussian 
distribution surrounding three centroids at [x, y] coordinates: [10, 20], [-10, -17], [17, -10]; 
with a standard deviation of 9. The simplicial complex (right) contains a flare. The top arm 
ends with another flare made by two nodes indicating the two clusters in the bottom of the 
picture. The second arm ends with a node indicating the upper cluster in the picture. The 
method consists of a number of steps, given a point cloud with N points 𝑥	 ∈ 𝑋 (Figures 3 
and 4): 
1. We start with a function 𝑓:	𝑋 → 	ℜ whose value is known for the N data points. We 
call this function a filter. The function should convey some interesting geometric or 
other, properties of the data, relevant for the task at hand. 
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2. Citing from [75]: “Finding the range (I) of the filter f restricted to the set X and 
creating a cover of X by dividing I into a set of smaller intervals (S) which overlap. 
This gives us two parameters which can be used to control resolution namely the 
length of the smaller intervals (l) and the percentage overlap between successive 
intervals (p)”. 
3. Citing from [75]: “Now, for each interval 𝐼* 	 ∈ 𝑆, we find the set  𝑋* = {𝑥|𝑓(𝑥) ∈ 𝐼*} 
of points which form its domain. The set Xj forms a cover of X, and 𝑋 ⊆ 	⋃ 𝑋** ”. 
4. Choosing a metric d(-,-) to get the set of all interpoint distances 𝐷𝑗	 = {𝑑(𝑥𝑎; 𝑥𝑏)|𝑥𝑎; 𝑥𝑏	 ∈ 	𝑋𝑗} 
5. For each Xj together with the set of distances Dj we find clusters {𝑋*:}. 
6. Each cluster then becomes a vertex in our complex and an edge is created between 
vertices if 𝑋*: ∩ 𝑋<= = ∅ meaning that two clusters share a common point. 
For a review of the technical details of the algorithm we refer to [75]. In this work we 
have used the Python language implementation of the Mapper algorithm called Kepler 
Mapper [76]. 
Statistical methods adopted in TDA 
• Chi-squared	 test	 (χ2):	 feature	 reduction	 is	 the	 step	 of	 reducing	 the	 number	 of	features	 to	 improve	 model	 construction.	 There	 are	 two	 main	 approaches	 for	feature	reduction:	 feature	selection	and	 feature	combination.	They	can	be	used	together.	 Feature	 selection	 is	 the	 process	 of	 selecting	 a	 subset	 of	 relevant	 and	informative	variables	 to	be	used	 in	model	construction.	 In	 feature	combination	the	 features	 are	 combined	 together	 (linearly	 or	 not)	 by	 building	 a	 new	 set	 of	artificial	 features.	Usually	 in	feature	combinations	the	features	are	weighted	by	coefficients	 reflecting	 features’	 relevance.	 Several	 approaches	 for	 feature	selection	are	available,	however	they	rely	mainly	on	statistical	tests.	χ2	statistical	
	32	
tests	 are	 widely	 used	 for	 selecting	 features	 that	 form	 the	 input	 space	 of	classifiers.	χ2	is	used	 in	statistics	 to	 test	 the	 independence	of	 two	events.	Given	dataset	 about	 two	 events,	 we	 can	 get	 the	 observed	 count	O	 and	 the	 expected	count	E.	 χ2	measures	 how	much	 the	 expected	 counts	E	 and	 observed	 Count	O	derivate	 from	each	other.	n	 feature	selection,	 the	 two	events	are	occurrence	of	the	feature	and	occurrence	of	the	class.	If	the	two	events	are	dependent,	we	can	use	the	occurrence	of	the	feature	to	predict	the	occurrence	of	the	class.	We	aim	to	 select	 the	 features,	 of	 which	 the	 occurrence	 is	 highly	 dependent	 on	 the	occurrence	of	the	class:	the	higher	value	of	the	χ2	score,	the	more	likelihood	the	feature	is	correlated	with	the	class,	thus	it	should	be	selected	for	model	training	[77].	 
• Receiver-operating characteristic (ROC) in TDA: in modern medicine, the validity of 
a dichotomous diagnostic test is determined by sensitivity and specificity. ROC curve 
is the plot that displays the full picture of trade-off between the true positive rate (Se) 
and false positive rate (1-Sp) across a series of inherent validity of a diagnostic test. 
This curve is useful in evaluating the discriminatory ability of a test to correctly pick 
up diseased and non-diseased subjects and finding the optimal cut-off point to least 
misclassify diseased and non-diseased subjects. The AUC is a single index for 
measuring the performance a test. The larger the AUC, the better is the overall 
performance of the medical test to correctly identify healthy and non-unhealthy 
subjects. Equal AUCs of two tests represent similar overall performances, however 
this does not necessary mean that both the curves are identical. We calculated the 
optimal cutoff value in each ROC curve adopting Youden's J statistic. ROC	 curves	were	compared	adopting	Delong	method[68]. 
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• Jaccard similarities. The Jaccard Similarity coefficient is a statistic used to compare 
the similarity and diversity of sample sets. The Jaccard coefficient measures similarity 
between sample sets, and it is defined as: 
𝐽(𝑀𝐷, 𝐴𝐷) = |𝑀𝐷 ∩ 𝐴𝐷||𝑀𝐷 ∪ 𝐴𝐷| 
Where: 
• MD is the medical doctor diagnosis (0 or 1) 
• AD is the diagnosis obtained with some other approach, e.g. algorithm (0 or 1) 
• Machine learning for data-driven modelling. ML	is	often	defined	as	a	“field	of	study	that	gives	computers	the	ability	to	learn	without	being	explicitly	programmed”.	It	means	 that	a	ML	algorithm	 learns	 from	the	data	a	set	of	parameters	necessary	for	adapting	the	algorithm	to	the	dataset	under	analysis.	As	an	example,	we	will	use	a	simple	linear	equation,	defined	as:	𝑦 = 𝑎𝑥 + 𝑏:	given	a	set	of	pairs	of	x	and	y	 (the	 so-called	 training	 set)	 a	 ML	 regressor	 algorithm	 will	 be	 able	 to	 extract	automatically	the	proper	values	of	a	and	b	so	that,	given	a	new	unseen	x,	it	will	approximate	the	equation.	Of	course,	ML	is	used	for	more	complicated	problems,	where	 it	 is	 quite	 impossible	 to	 explicitly	 write	 the	 analytical	 form.	 With	 this	example	we	have	introduced	the	concept	of	“regressor”	that	is	an	algorithm	able	for	 predicting	 continuous	 numbers.	 A	 second	 class	 of	 algorithms	 is	 called	
classifier:	 the	ML	algorithm	learns	from	a	training	set	 to	automatically	classify	a	new	 unseen	 input	 in	 a	 set	 of	 classes.	 ML	 algorithms	 learn	 from	 data	 a	 set	 of	parameters	 for	 better	 approximating	 the	 map	 projecting	 the	 inputs	 with	 the	output(s).	 However,	 the	 selection	 of	 which	 ML	 algorithm	 to	 be	 used	 and	 its	partial	 initial	 configuration	 (e.g.	 number	 of	 layers	 and	 nodes	 of	 an	 artificial	neural	network)	is	demanded	to	the	data	scientist	experiences.	Moreover,	a	ML	pipeline	 is	often	composed	by	a	collection	of	algorithms	 interacting	each	other.	
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Thus,	 given	 a	 dataset	 the	 engineering	 of	 a	ML	 pipeline	 in	 terms	 of	 algorithms	down-selection	and	their	configuration	becomes	a	daunting	task.	Recently,	a	new	class	of	framework	called	AutoML	is	emerging.	AutoML	systems	aim	to	assist	data	scientist	 in	 the	 selection	 of	 the	 proper	 algorithms	 and	 their	 automatic	 tuning.	Among	 the	 other,	 Tree-based	 Pipeline	 Optimization	 Tool	 (TPOT)	 framework	 is	receiving	interest	from	the	data	science	community.	TPOT	automatically	designs	and	optimizes	ML	pipelines	 for	 a	 given	problem	domain,	without	 any	need	 for	human	 intervention.	 In	 short,	 TPOT	 optimizes	ML	 pipelines	 using	 a	 version	 of	genetic	 programming,	 a	 well-known	 evolutionary	 computation	 technique	 for	automatically	 constructing	 computer.	 TPOT	 can	 deal	with	 both	 regression	 and	classification	problems.	In	the	following,	we	list	the	main	algorithms	handled	by	TPOT	used	as	methods	of	our	data	analysis: 
• Supervised Classification Operators. Decision Tree, Random Forest, eXtreme 
Gradient Boosting Classifier, Logistic Regression, and K-Nearest Neighbor 
Classifier.  
• Feature Preprocessing Operators. StandardScaler, RobustScaler, MinMaxScaler, 
MaxAbsScaler, RandomizedPCA, Binarizer, and Polynomial Features.  
• Feature Selection Operators. VarianceThreshold, SelectKBest, SelectPercentile, 
Select and Recursive Feature Elimination (RFE). 
TPOT developers are very active and new algorithms are added frequently [78]. 
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3. Results 
Study cohort 
The Internal and Subintensive Medicine department of an 800-beds teaching hospital 
(Azienda Ospedaliero-Universitaria “Ospedali Riuniti”, Ancona, Italy) adopted an electronic 
database for inpatients’ management since 01/01/2002; from that date to 31/03/2018, 6822 
critically-ill patients affected by AF have been admitted to this unit.  
 According to the study design, we selected the first quarter, equal to 1705 patients. 
After excluding those admitted performing a planned cardioversion procedure for AF rhythm 
control, stable patients without acute organ failure and patients admitted for trauma or 
surgical pathologies, we obtained a total of 1430 patients, included in the analysis. We 
synthesized the criteria for patients’ selection in Figure 2. 
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Figure 2: criteria for selection of the analysed sample 
 
   
Baseline characteristics of the sample 
Main outcome was met in 13.6% of the sample (194 subjects). TEE occurred in 
14.8% of the cohort (212 patients). We observed MH in 9.30% of the analyzed group (133 
subjects). Baseline characteristics of the sample at the admission according MO are 
synthesized in Table 5.  
 
Table 5: Baseline Characteristics at Admission in Sub-Intensive Unit (sICU) 
 MO p 
 No Yes 
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N= 1236 N= 194 
Age, years median [IQR] 81 [75-85] 83 [77-89] <0.001 
Female Sex, n (%) 753 (49.9) 90 (46.2) 0.329 
Type of AF, n (%) 
Paroxysmal 
Persistent 
Permanent 
 
220 (18.6) 
292 (24.7) 
668 (56.6) 
 
24 (12.8) 
57 (30.3) 
107 (56.9) 
0.077 
Previous Clinical History    
Hypertension, n (%) 637 (51.5) 64 (33.0) <0.001 
Diabetes Mellitus, n (%) 226 (18.3) 34 (17.5) 0.799 
Chronic Anaemia, n (%) 114 (9.2) 17 (8.8) 0.836 
Coronary Artery Disease, n (%) 531 (43.0) 78 (40.2) 0.471 
Peripheral Artery Disease, n (%) 131 (10.6) 16 (8.2) 0.316 
Chronic Heart Failure, n (%) 581 (47.0) 88 (45.4) 0.669 
CVF, n (%) 183 (14.8) 27 (13.9) 0.745 
CVE, n (%) 29 (2.3) 1 (0.5) 0.098 
Previous stroke/TIA, n (%) 258 (20.9) 34 (17.5) 0.282 
Mitral Valve Disease, n (%) 195 (15.8) 15 (7.7) 0.003 
Aortic Valve Disease, n (%) 151 (12.2) 16 (8.2) 0.109 
COPD, n (%) 340 (27.5) 54 (27.8) 0.925 
Chronic hepatic pathologies, n (%) 35 (2.8) 7 (3.6) 0.551 
CKD, n (%) 230 (18.6) 39 (20.1) 0.620 
Previous GI Bleeding, n (%) 66 (5.3) 5 (2.6) 0.100 
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Active Cancer, n (%) 210 (17.0) 44 (22.7) 0.054 
Comorbidities, n median [IQR] 3 [2-4] 2 [2-3] 0.114 
Concurrent Clinical Events    
TEE, n (%) 177 (14.3) 35 (18.0) 0.175 
MH, n (%) 110 (8.9) 23 (11.9) 0.188 
Syncope, n (%) 68 (5.5) 2 (1.0) 0.007 
Acute Neurologic Disorders, n (%) 47 (3.8) 6 (3.1) 0.627 
Acute Coronary Syndrome, n (%) 160 (12.9) 50 (25.8) <0.001 
Acute Heart Failure, n (%) 669 (54.1) 99 (51.0) 0.421 
Cardiogenic Shock, n (%) 28 (2.3) 43 (22.2) <0.001 
Septic Shock, n (%) 106 (8.6) 74 (38.1) <0.001 
AKI, n (%) 58 (4.7) 10 (5.2) 0.779 
Acute Respiratory Failure, n (%) 319 (25.8) 77 (39.7) <0.001 
Infections, n (%) 330 (26.7) 102 (52.6) <0.001 
Legend: AF= atrial fibrillation; ACS= acute coronary syndrome; AKI= acute kidney injury; 
CKD= chronic kidney disease; COPD= chronic obstructive pulmonary disease; CVE= 
electrical cardioversion procedure; CVF= pharmacological cardioversion procedure; IQR= 
interquartile range; TEE= thromboembolic events; TIA= transient ischemic attack. 
 
Thromboembolic and bleeding risk and relationships with outcomes  
At baseline, there was no difference in terms of thromboembolic risk according to 
CHA2DS2-VASc score between patients that experience the composite outcome and those 
that did not experience it. Conversely, HAS-BLED score, as well the proportion of patients 
with high bleeding risk were lower (both p<0.001) patients that reported the main outcome 
than in those that did not report the outcome (Table 6). Examining the entire spectrum of the 
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two scores, no difference was found in the distribution of the MO according to CHA2DS2-
VASc score points (p=0.501). Conversely, the MO occurred more frequently in patients with 
a lower HAS-BLED score (p<0.001). 
 Further, considering the occurrence of concurrent clinical events we examined the 
prevalence of TEE according to CHA2DS2-VASc score and the prevalence of major bleeding 
according to HAS-BLED score, finding no significant differences across the two scores’ 
points and the occurrence of events (respectively p=0.641 and p=0.479).  
Also, we found no association between CHA2DS2-VASc score and TEE occurrence 
and between HAS-BLED score and major bleeding occurrence (Table 10). Similarly, we 
found no predictive ability of the two scores regarding the respective events (CHA2DS2-
VASc c-index for stroke/TIA: 0.545, 95% CI: 0.489-0.601; HAS-BLED c-index for major 
bleeding: 0.503, 95% CI: 0.453-0.554).  
We also considered CHADS2 score, which is deemed to be less age and vascular 
comorbidities dependent than CHA2DS2-VASc: however, when tested against TEE 
occurrence with ROC curve analysis, CHADS2 did not result significantly predictive of 
events (AUC: 0.513; 95%CI: 0.487-0.539; p >0.05), with performances similar to CHA2DS2-
VASc (AUC: 0.516; 95%CI: 0.472-0.560; p >0.05). Moreover, when comparing the two 
scores, the difference between AUCs did not result significantly different in predicting 
thromboembolic events (difference between areas: 0.00326; p= 0.7108). For this reason, we 
continued the analyses adopting only the most currently adopted scores, CHA2DS2-VASc and 
HAS-BLED. 
Considering high thromboembolic risk, we found a high sensitivity (93.4%, 95% CI: 
90.9-99.0%) and a high NPV (95.0%, 95% CI: 87.6-98.1%) of CHA2DS2-VASc ≥2 for 
stroke/TIA, with a low specificity and PPV (Table 10). Regarding the high bleeding risk, 
intermediate values for both sensitivity (46.6%, 95% CI: 37.9-55.5%) and specificity (57.1%, 
	40	
95% CI: 54.4-59.8%) were found, while a high NPV (91.3%, 95% CI: 89.8-92.5%) and a 
very low PPV were reported (Table 10). 
 
Table 6: Thromboembolic and Bleeding Risk at Baseline 
 MO P 
 No 
N= 1236 
Yes 
N= 194 
CHA2DS2-VASc, median [IQR] 4 [3-5] 4 [3-5] 0.057 
CHA2DS2-VASc, mean (SD) 4.28 (1.68) 4.04 (1.72) 0.774 
CHA2DS2-VASc ≥2, n (%) 1170 (94.7) 180 (92.8) 0.290 
HAS-BLED, median [IQR] 2 [2-3] 2 [1-3] <0.001 
HAS-BLED, mean (SD) 2.38 (1.08) 2.07 (0.95) <0.001 
HAS-BLED ≥3, n (%) 563 (45.6) 55 (28.4) <0.001 
Legend: IQR= interquartile range; SD= standard deviation. 
 
Factors affecting the main outcome 
Regarding medical therapy, we observed that patients undergoing to the main 
composite outcome were more likely treated with anticoagulants and less likely treated with 
antiplatelet drugs at the admission in sICU, as shown in Table 7. 
 
Table 7: Antithrombotic Therapies at Admission in Sub-Intensive Unit   
 MO P 
 No 
N= 1236 
Yes 
N= 194 
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Anticoagulant Drugs, n (%) 
None 
Any Anticoagulant 
 
454 (36.7) 
782 (63.3) 
 
46 (23.7) 
148 (76.3) 
<0.001 
 
Type of Anticoagulant, n (%) 
LMWH 
OAC 
 
312 (39.9) 
470 (60.1) 
 
65 (43.9) 
83 (56.1) 
0.361 
Antiplatelet Drugs, n (%) 515 (41.7) 55 (28.4) <0.001 
Legend: LMWH= low-molecular weight heparin; OAC= oral anticoagulant. 
 
When analysing at the multivariate logistic analysis the risk factors for the occurrence 
of MO, we identified - among the reasons for sICU admission - ACS, CS, SS and ARF. 
Increasing age was positively associated with the outcome, while hypertension and mitral 
valve disease were negatively associated with MO, as shown in Table 8. 
 
Table 8: Multivariate Logistic Analysis for Composite Outcome Occurrence 
 OR 95% CI P 
Age (per year) 1.04 1.02-1.06 0.001 
Hypertension 0.52 0.36-0.76 0.001 
Mitral Valve Disease 0.49 0.25-0.94 0.033 
ACS 3.40 2.06-5.60 <0.001 
Cardiogenic Shock 20.68 11.03-38.78 <0.001 
Septic Shock 7.66 4.67-12.56 <0.001 
Acute Respiratory Failure 2.34 1.57-3.50 <0.001 
Anticoagulant Drugs    
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None (reference) 
LMWH 
OAC 
- 
1.13 
1.73 
- 
0.68-1.87 
1.06-2.83 
- 
0.640 
0.030 
Antiplatelet Drugs 0.51 0.34-0.78 0.002 
Legend: ACS= acute coronary syndrome; CI= confidence interval; LMWH= low-molecular 
weight heparin; OAC= oral anticoagulant; OR= odds ratio; TEE= thromboembolic events; 
TIA= transient ischemic attack. 
 
CHA2DS2-VASc and HAS-BLED in the prediction of thrombotic and haemorragic events  
The rate of TEE according to CHA2DS2-VASc score and MH according to HAS-
BLED score are synthesized in Table 9. The distribution of TEE does not differ significantly 
among CHA2DS2-VASc classes and, similarly, the distribution of MH does not significantly 
differ among HAS-BLED classes. 
 
Table 9: Major Adverse Events Rate according to Risk Scores 
CHA2DS2-VASc TEE [n (%)] HAS-BLED MH [n (%)] 
0 0 (0.0) 0 3 (7.3) 
1 4 (6.1) 1 27 (9.9) 
2 10 (7.4) 2 41 (8.2) 
3 15 (6.1) 3 49 (11.5) 
4 27 (8.1) 4 10 (6.2) 
5 24 (7.7) 5 3 (11.1) 
6 14 (7.5) 6 0 (0.0) 
7 13 (12.6)   
	 43	
8 3 (11.5)   
9 0 (0.0)   
Legend: TEE= thromboembolic events; MH= major haemorrhage. 
 
We did not observe a significant association between CHA2DS2-VASc and the 
occurrence of stroke/TIA, nor a significant association between HAS-BLED and MH 
adopting c-statistic, as shown in Table 10.  
We adopted the currently suggested cut-offs for both scores. CHA2DS2-VASc, when 
analysed at a cutoff ≥2, had a high sensitivity and a good negative predictive value. HAS-
BLED, adopting a cutoff ≥3 had a low sensitivity and specificity, but a good negative 
predictive value, as shown in Table 10.  
We also evaluated the quality of the clinical scores, CHA2DS2-VASc and HAS-
BLED, used for identifying high-risk patients by comparing them with the ground truth TEE 
and MH, respectively.  
Results are represented and summarized in Figure 5. The classification error, that is 1-
accuracy, reports the ration between the number of incorrect classified patients when 
compared with the overall population.  
In our sample, the accuracy of each score was between 49 and 52% (CHA2DS2-VASc 
= 52%, HAS-BLED = 49%), meaning that the two scoring systems had the same probability 
of classifying or misclassifying TEE or MH in this sample of critically-ill patients. 
 
Table 10: Association between Risk Scores, Major Adverse Events and Predictive Analysis 
 OR (95 %)* P c-index (95%) P 
CHA2DS2-VASc 
 for TEE 
1.09  
(0.96-1.22) 
0.175 0.545  
(0.489-0.601) 
0.117 
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HAS-BLED  
for MH 
1.07  
(0.90-1.27) 
0.477 0.503  
(0.453-0.554) 
0.900 
 Se  
(95% CI) 
Sp  
(95% CI) 
PPV  
(95% CI) 
NPV  
(95% CI) 
CHA2DS2-VASc ≥2  
for TEE 
93.4%  
(90.9-99.0%) 
5.8%  
(4.6-7.1%) 
7.8%  
(6.4-9.2%) 
95.0%  
(87.6-98.1%) 
HAS-BLED ≥3  
for MH 
46.6%  
(37.9-55.5%) 
57.1% 
(54.4-59.8%) 
10.0%  
(8.4-11.9%) 
91.3%  
(89.8-92.5%) 
Legend: *adjusted for type of AF and anticoagulant treatment; CI= confidence interval; 
OR= odds ratio; NPV= negative predictive value; PPV= positive predictive value; TIA= 
transient ischemic attack. 
 
Figure 5: ROC Curve Analysis for CHA2DS2-VASc, HAS-BLED and Classification Error 
  
ROC curve for CHA2DS2-VASC score ROC curve for HAS-BLED score 
 AUC 
CHA2DS2-VASC 0.516 [95%CI: 0.472-0.560] 
HAS-BLED 0.493 [95%CI: 0.443-0.543] 
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 Classification Error 
CHA2DS2-VASC 0.963 [95%CI:0.955-0.973] 
HAS-BLED 0.923 [95%CI: 0.910-0.936] 
Legend: ROC= receiver operating curve; AUC= area under the curve. 
 
Medical treatment and outcomes in the critically-ill patient 
 On the basis of the ESC 2016 guidelines, we found out that 642 (44.9%) were treated 
as adherent to the current recommendations, while 540 (37.8%) were undertreated and 248 
(17.3%) were overtreated. Analyzing the rate of major adverse outcomes according to 
guidelines’ adherence, while we found that the TEE rate was the lowest in those patients 
treated as adherent (p<0.001) (Figure 6), in the same patients the prevalence of both major 
bleeding and composite outcome was the higher (p<0.001 and p=0.020, respectively) (Figure 
6). The final multivariable model (Table 11) found out that while undertreatment was 
associated with an increased risk of TEE, an inverse association with both major bleeding and 
composite outcome was found out. Conversely, overtreatment only showed a trend with 
occurrence of TEE, even though did not reach the statistical significance (Table 11). 
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Figure 6: Events distribution according to current guidelines adherence  
 
 
Legend: TEE= thromboembolic events; MH= major bleeding; MO= main outcome; GL= 
guidelines. 
 
Table 11: Multivariable-Adjusted Association between Guidelines Adherence and Major 
Adverse Events 
 TEE MH MO 
 OR  
(95% CI) 
p OR  
(95% CI) 
P OR  
(95% CI) 
P 
GLs Adherent 
(ref.) 
- - - - - - 
Undertreated 2.38  
(1.45.-3.91) 
0.001 0.30  
(0.18-0.48) 
<0.001 0.63  
(0.42-0.97) 
0.034 
Overtreated 1.75  0.097 0.67  0.143 0.83  0.481 
11,10%
4,80%
11,50%
4,80%
13,20%
16,40%
7,70%
8,90%
10,90%
0,00%
2,00%
4,00%
6,00%
8,00%
10,00%
12,00%
14,00%
16,00%
18,00%
TEE MH MO
Undertreatment GL-adherent Overtreatment
p < 0,0001
p < 0,0001
p < 0,0001
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(0.90-3.39) (0.39-1.15) (0.48-1.41) 
Legend: CI= confidence interval; GLs= guidelines; TIA= transient ischemic attack. 
 
Towards new predictive models in the critically-ill patient 
After observing a poor efficiency of CHA2DS2-VASc and HAS-BLED scores in 
predicting TEE as well as MH (at least for the considered dataset), we focused on instructing 
a new data-driven supervised solution for automatically predicting the three outcomes: TEE, 
MH and MO.  
For each target variable, we dropped the other two scores and evaluated the 
correlation among the clinical variables and target under modeling. Before executing the 
methodology, we have transformed all the categorical variables in their dummy 
representation. A dummy variable is an artificial variable created to represent an attribute 
with two or more distinct categories/levels. The dummy variable represents the original value 
as a tuple of binary values. For example, if the original categorical variable has n values it 
will be represented by n-1 new binary variables.  
t-SNE results: we evaluated the effect of the perplexities spanning between the values 
30-50 with step 5 for the t-SNE algorithm. The t-SNE visualization of the three subsets is 
reported in Table 12. The red points are patients with target variable equal to 0, while the 
blue points are the patients with target variable equal to 1. In the plots for the MH and TEE 
the clusters formed by the blue points are well evident. In the MH plot the blue group is also 
quite distant from the red cloud indicating a good separation between the two clouds. While, 
in the last plot representing MO, the blue points are more scattered: at perplexity 35 it is 
possible to observe two blue subgroups overlapping with red points.  
These results encourage the possibility to train a ML classifier to predict 
automatically the target variables. Due to the scarce separation on the red-blue points in MO, 
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we hypothesize that for this target variable the ML pipeline will require more steps than the 
others. 
 
Table 12: Comparison of t-SNE for different target variables with perplexity values from 30 
to 50 with step 5. 
Outcome t-SNE plot with perplexities from 30 to 50 
MH 
 
TEE 
 
MO 
 
Legend: MH= major hemorrhage; TEE= thromboembolic events; MO= main outcome. 
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Mapper results 
In order to mine other insights from the raw data before their manipulation we 
executed the Mapper algorithms. The inputs to the algorithm are the clinical variables plus 
their dummy representation, when necessary, plus the target variable under analysis. For 
Mapper algorithm, we used the Jaccard coefficient as metric and the DBscan as clustering 
algorithm, overlap percentage equal to 10%. The lens is the sum of the entries plus their 
MinMax scaling. 
 
Table 13: Comparison of Mapper for different target variables 
Outcome Topological Data Analysis (Mapper) 
MH 
 
TEE 
 
	50	
MO 
 
Legend: MH= major hemorrhage; TEE= thromboembolic events; MO= main outcome. 
 
The Mapper analysis identified interesting features and relationships in the dataset 
confirming t-SNE results and extended previous results by highlighting interesting 
topological features.  
We remark that, from a topological perspective, we focus on forks (flares) and big 
loops. In our case, each simplicial complex contained at least one fork. The main 
characteristics of the topological features are shown in Table 13:  
• MH:	The	simplicial	complex	contains	two	small	loop	and	a	fork.	The	longest	flare	contains	 two	 nodes	 for	 a	 total	 of	 80	 patients,	while	 the	 other	 node	 contains	 9	samples.	
• TEE:	 	The	simplicial	complex	contains	2	forks.	The	nodes	with	largest	diameter	in	 the	 bottom	 flare	 contain	 27	 samples,	 while	 the	 other	 two	 nodes	 contain	 7	samples	each.	
• MO:	 The	 simplicial	 complex	 contains	 only	 one	 fork.	 The	 longest	 flare	 contains	two	nodes	with	totally	39	samples,	while	the	other	node	contains	8	samples.	
Mapper returns also the index of the patients belonging to each node and - driven by 
this information – we subsampled the dataset by selecting the subjects in the forks and 
compared them by using chi-squared tests. Results are synthesized in Table 14, Table 15 and 
Table 16. We report only the features with p-value < 0.05. 
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Table 14: statistically relevant features that differentiate the nodes in the fork of the MH 
simplicial complex 
Features c2 p-value 
MH type 376.8212 0 
Anticoagulant type at discharge 44.89189 0 
MH 389 0 
Acute Heart Failure 36.35367 0 
Haemorragic Shock 92.71738 0 
ASA or Clopidogrel use 20.71988 0.000005 
Previous GI Bleeding 13.06815 0.0003 
Age 10.86397 0.001071 
Number of comorbidities 17.96861 0.021463 
Diabetes Mellitus 4.287005 0.038405 
CVE 4.265441 0.038895 
Active Cancer 4.134792 0.04201 
Legend: MH= major hemorrhage; ASA= acetylsalicylic acid; GI= gastrointestinal; CVE= 
electrical cardioversion. 
 
Table 15: statistically relevant features that differentiate the nodes in the fork of the TEE 
simplicial complex 
Features c2 p-value 
TEE type 42 0 
TEE 42 0 
AF Type 23.55294 0.000031 
CVE 10.65613 0.001097 
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Anticoagulant type at admission 7.285045 0.006953 
Sex 5.164035 0.023059 
Previous stroke/TIA 5.164035 0.023059 
Aortic valve disease 5.164035 0.023059 
Legend: TEE= thromboembolic event; AF= atrial fibrillation; TIA= transient ischemic 
attack; CVE= electrical cardioversion. 
 
Table 16: Statistically relevant features that differentiate the nodes in the fork of the main 
outcome simplicial complex 
Features c2 p-value 
Septic Shock 11.84188 0.000579 
CKD 5.9538 0.014686 
Infection 6.880842 0.032051 
Legend: CKD= chronic kidney disease. 
 
The joined analysis of topological structures and statistical tests provided a first 
significant indication on which features should be used for training the ML classifiers: we 
observed that the features in the MH simplicial complex with highest c2 score reflected 
hemorrhage-related issues, such as bleeding predisposition, active cancer and drugs (Table 
14). Features with the highest score in the TEE simplicial complex were related to 
cardioembolism and AF type (Table 15). Features with the highest score for MO in this 
analysis are synthesized in Table 16. 
Feature selection 
Mapper TDA was able to enlighten the importance of some variables. However, the 
evaluation of the simplicial forks provides only informations useful to understand some 
clusters and their statistical differences. In order to instruct automatic classifiers with ML we 
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extended the local results - provided by Mapper - to global analysis. In order to capture 
global statistical insights, we evaluated the dependency among the clinical variables and the 
target variable under modeling by performing both the c2 test with the Yates correction for 
continuity to evaluate the dependency among categorical features and target variable.  
The F-value was used to study the dependencies of the discrete variables on the target 
variable. Results of this analysis are reported in Table 17, where we report only the features 
that received a p-value < 0.05. We obtained a reduced number of variables related with the 
target variables and this was useful on modeling the classifiers. The features identified by 
Mapper were partially included among the features indicated above in Table 17. 
 
Table 17: Relevant features related to the target variables 
Outcome Topological Data Analysis via Mapper 
MH 
Feature c2/F-value p-value 
MH type 1595.4561 0 
Anticoagulant therapy at admission 37.241885 0 
Anticoagulant therapy at discharge 79.376273 0 
MH 1655 0 
Haemorragic Shock 293.64996 0 
Chronic Anaemia 39.094657 0 
Low TTR 27.003168 0 
Previous GI Bleeding 18.03138 0.000022 
CVE 13.756998 0.000208 
ASA or Clopidogrel use 11.396544 0.000736 
Acute Heart Failure 11.093365 0.000866 
Age 10.006409 0.001588 
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TEE Type 48.293552 0.007119 
Acute Respiratory Failure 5.248561 0.021965 
Active Cancer 4.629148 0.031433 
CKD 4.233212 0.03964 
Syncope 4.053498 0.04408 
 
TEE 
Feature c2/F-value p-value 
TEE Type 1613.2040 0 
CVE 28.056792 0 
Anticoagulant therapy at admission 65.840332 0 
Anticoagulant therapy at discharge 37.435286 0 
TEE 1646.1671 0 
Acute Heart Failure 37.235441 0 
Previous stroke/TIA 32.398337 0 
Low TTR 25.672567 0 
Age 16.45507 0.00005 
CHF 11.197515 0.00081 
ACS 9.988791 0.00157 
Mitral Valve Disease 8.180653 0.004234 
Sex 6.34187 0.01179 
AF Type 10.794743 0.01288 
Syncope 5.534671 0.01864 
CVF 5.237731 0.02210 
COPD 4.581552 0.03231 
Aortic Valve Disease 3.96779 0.04637 
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MO 
Feature c2/F-value p-value 
Age 22.723161 0 
Anticoagulant therapy at discharge 71.900145 0 
ACS 31.465911 0 
Cardiogenic Shock 178.662335 0 
Septic Shock 161.661497 0 
Acute Respiratory Failure 39.144258 0 
Infection 101.341306 0 
Hypertension 22.521132 0.000013 
CVE 21.94512 0.000017 
Hemorrhagic Shock 21.932328 0.000017 
COPD 14.544708 0.000694 
TEE type 91.295819 0.00114 
Mitral Valve Disease 9.939222 0.006946 
ASA or Clopidogrel use 8.233689 0.016296 
Sex 7.700486 0.021275 
TEE 23.053895 0.027272 
MH 20.076694 0.028536 
Peripheral Artery Disease 6.524466 0.038303 
 
Legend: MH= major haemorrhage; TEE= thromboembolic event; TTR= time in therapeutic 
range; GI= gastrointestinal; CVE= electric cardioversion; CVF= pharmacological 
cardioversion; ASA= acetyl salicylic acid; CKD= chronic kidney disease; TIA= transient 
ischemic attack; CHF= chronic heart failure; AF= atrial fibrillation; COPD= chronic 
obstructive pulmonary disease. 
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Training automatic classifiers with machine learning 
The features identified with the statistical test were used as input for the TPOT 
framework. The modeling experiment was executed twice by changing the number of 
generations: respectively 10 and 20. The population size was fixed and equal to 20 while the 
number of k-folds for the cross validation on the training set was k=5. Models performance 
was evaluated using the classification error, defined as the percent of incorrect classifications, 
with a minimum possible score equal to 0.  
The performances of the selected pipelines are reported in terms of average accuracy 
(1 – classification error), average classification error and 95% of confidence intervals (CI) on 
the training set and ROC and AUC for the test set (Figure 7). The results are reported in 
Table 18 and Table 19. 
 
Table 18: Best Pipeline(s) fitted after 10 generations 
Target Accuracy 
% 
Classification 
Error 
95%CI Best Pipeline 
MH 100 0 0 LinearSVC (input_matrix, C=25.0, dual = Tur, loss = 
squared_hinge, penalty = 12, tol = 0.001) 
TEE 100 0 0 GradientBoostingClassfier (input_matrix, learning_rate = 1.0, 
max_depth = 9, max_features = 0.8, min_samples_leaf = 1, 
min_samples_split = 3, n_estimators = 100, subsample = 0.65) 
MO 87.68 0.123 0.09153-
0.154847 
RandomForestClassfier(OneHotEncoder(input_matrix, 
minimum_fraction = 0.15, sparse = False), bootstrap = False, 
criterion = entropy, max_features = 0.25, min_samples_leaf = 2, 
min_samples_split = 13, n_estimators = 100) 
Legend: MH= major hemorrhage; TEE= thromboembolic events; MO= main outcome. 
 
Table 19: Best Pipeline(s) fitted after 20 generations 
Target Accuracy
% 
Classification 
Error 
95%CI Best Pipeline 
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MH 100 0 0 RandomForestClassfier(input_matrix, bootstrap = True, 
criterion = entropy, max_features = 0.95, 
min_samples_leaf = 2, min_samples_split = 16, 
n_estimators = 100) 
TEE 99.75 0. 2415 0.2313 – 
0.3144 
DecisionTreeClassifier(input_matrix, criterion = gini, 
max_depth = 9, min_samples_leaf = 1, 
min_samples_split = 11) 
MO 90.33 0.09 0.068159 – 
0.125077 
KNeighborsClassifier(MaxAbsScaler(RFE(Normalizer(i
nput_matrix), norm = max), criterion = gini, 
max_features = 0.95, n_estimators = 100, step = 0.95)), 
n_neighbors = 34, p =1, weights = distance) 
Legend: MH= major hemorrhage; TEE= thromboembolic events; MO= main outcome. 
 
Figure 7: Results of classifiers 
  
A) MH after 10 generations (AUC: 100%) B) MH after 20 generations (AUC: 100%) 
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C) TEE after 10 generations (AUC: 100%) D) TEE after 20 generations (AUC: 99.75%) 
  
E) MO after 10 generations (AUC: 87,68%) F) MO after 20 generations (AUC: 90,33%) 
Legend: MH= major hemorrhage; TEE= thromboembolic events; MO= main outcome; 
AUC= area under the curve. 
 
The obtained classifiers outperformed the CHA2DS2-VASC and HAS-BLED scoring 
systems in the prediction of TEE and MH, respectively. The small fluctuation from accuracy 
= 100% to accuracy = 99.75% in the TEE classifier was due to random initialization during 
the splitting of the training set but is not relevant since the classification error remains 
extremely low. The pipelines for predicting both MH as well as the TEE were relatively 
simple: they train decision-tree based algorithms for modelling the scores and this means the 
populations forming healthy and unhealthy patients are approximately linearly or polynomial 
separable. 
The MO classifier showed good performances, and its accuracy raised from 87.68% 
to 90.33% by increasing the number of generations. These performances were not as 
excellent as the other two outcomes, since the numbers of patients belonging to class 2 is 
relatively low (few tens) and there are several overlaps among patients as pinpointed out by 
the t-SNE plot. This indicated that other features should be added to the dataset.  
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Mapper analysis suggested looking for features regarding septic shock, infections and 
kidney disease. Conversely, the pipelines fitted to predict the MO counted a number of 
intermediate steps to improve the separation among populations belonging to different 
classes.  
In details, the best-fitted pipelines perform a normalization of the data by setting mean 
to 0 and standard deviation to 1 (Normalize). Then, it performs a recursive features 
elimination for reducing the number of features (RFE), the it executes a scaling of each 
feature such that the maximal absolute value of each feature in the training set will be 1.0. 
Eventually, the pipeline trains a proximity-based classifier (KNeighborsClassifier). 
The first results were critically reviewed: since variable selection and model 
generation was machine-driven, the clinical role of each variable was discussed. The 
extremely impressive high accuracy of the TEE and MH classifier was – at least in part –
motivated by the presence of some features that are synonyms of the outcomes we aimed to 
predict: the training set used for instructing the classifier for the MH contained among the 
other the features MH type, MH, HS and TEE type with highest c2: these features map 
exactly the outcome itself. Similarly, the training set for TEE contained two features (TEE 
type and TEE), that represented the outcome itself. 
Thus, we removed those features from the list and retrained the classifiers. Moreover, in 
order to estimate how features impact the overall quality, we adopted the following 
procedure: 
1) Sort in ascending order the features according their p-value (from 0 to n). 
2) Span on the feature set and pick up one feature at time, accordingly to its p-value, and 
re-train the classifier.  
The output of this algorithm is a plot, for each target variable, where horizontal axis is the 
number of features and the vertical axis is the corresponding AUC. The features used in this 
evaluation are reported in Table 20. The corresponding plots are reported in Table 21. 
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Table 20: reduced feature set by removing the features that are the images of the target 
variables 
Outcome Topological Data Analysis via Mapper 
MH 
Feature c2/F-value p-value 
Anticoagulant therapy at admission 37.241885 0 
Anticoagulant therapy at discharge 79.376273 0 
Chronic Anaemia 39.094657 0 
Low TTR 27.003168 0 
Previous GI Bleeding 18.03138 0.000022 
CVE 13.756998 0.000208 
ASA or Clopidogrel use 11.396544 0.000736 
Acute Heart Failure 11.093365 0.000866 
Age 10.006409 0.001588 
Acute Respiratory Failure 5.248561 0.021965 
Active Cancer 4.629148 0.031433 
CKD 4.233212 0.03964 
Syncope 4.053498 0.04408 
 
TEE 
Feature c2/F-value p-value 
CVE 28.056792 0 
Anticoagulant therapy at admission 65.840332 0 
Anticoagulant therapy at discharge 37.435286 0 
Acute Heart Failure 37.235441 0 
Previous stroke/TIA 32.398337 0 
Low TTR 25.672567 0 
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Age 16.455079 0.00005 
CHF 11.197515 0.00081 
ACS 9.988791 0.00157 
Mitral Valve Disease 8.180653 0.004234 
Sex 6.34187 0.01179 
AF Type 10.794743 0.01288 
Syncope 5.534671 0.01864 
CVF 5.237731 0.02210 
COPD 4.581552 0.03231 
Aortic Valve Disease 3.96779 0.04637 
 
MO 
Feature c2/F-value p-value 
Age 22.723161 0 
Anticoagulant therapy at discharge 71.900145 0 
ACS 31.465911 0 
Cardiogenic Shock 178.662335 0 
Septic Shock 161.661497 0 
Acute Respiratory Failure 39.144258 0 
Infection 101.341306 0 
Hypertension 22.521132 0.000013 
CVE 21.94512 0.000017 
Hemorrhagic Shock 21.932328 0.000017 
COPD 14.544708 0.000694 
TEE type 91.295819 0.00114 
Mitral Valve Disease 9.939222 0.006946 
ASA or Clopidogrel use 8.233689 0.016296 
Sex 7.700486 0.021275 
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TEE 23.053895 0.027272 
MH 20.076694 0.028536 
Peripheral Artery Disease 6.524466 0.038303 
 
Legend: MH= major haemorrhage; TEE= thromboembolic event; TTR= time in therapeutic 
range; GI= gastrointestinal; CVE= electric cardioversion; CVF= pharmacological 
cardioversion; ASA= acetyl salicylic acid; CKD= chronic kidney disease; TIA= transient 
ischemic attack; CHF= chronic heart failure; AF= atrial fibrillation; COPD= chronic 
obstructive pulmonary disease. 
 
Table 21: Evaluation of classifiers’ performances trained with a different number of features. 
The x-axis is the feature number, while the y-axis is the AUC 
MH 
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TEE 
 
MO 
 
 
Legend: MH= major haemorrhage; TEE= thromboembolic events; MO= main outcome. 
 
For MH, the classifier with highest accuracy (AUC: 90%) was obtained by using 9 
features: anticoagulant therapy at admission, anticoagulant therapy at discharge, CA, low 
TTR, previous GI bleeding, CVE, ASA or Clopidogrel use, AHF and age, as shown in Table 
21 and Table 22. At the best cutoff, selected with the Youden’s index (optimal cut-off: 
0.092056), the new classifier had a Sensitivity = 0.80, a 1-Specificity = 0.18984, a positive 
likelihood ratio of 4.21 and a negative likelihood ratio of 0.25. 
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The best classifier for TEE (AUC: 82%) was obtained by using the following 9 
features: CVE, anticoagulant therapy at admission, anticoagulant therapy at discharge, AHF, 
previous stroke/TIA, low TTR, age, CHF and ACS, as shown in Table 21 and Table 22. At 
the best cutoff, selected with the Youden’s index (optimal cut-off: 0.137663), the new 
classifier had a Sensitivity = 0.75, a 1-Specificity = 0.245899, a positive likelihood ratio of 
3.05 and a negative likelihood ratio of 0.33.  
For MO, the highest accuracy (AUC: 97.5%) was obtained with the following 
variables: age, anticoagulant therapy at discharge, ACS, CS, SS, ARF, infection and HYP, as 
shown in Table 21. 
This analysis highlighted that the 100% accuracy for MH and TEE classifiers 
decreased by reducing the number of features. However, the new scores outperformed the 
accuracy of HAS-BLED and CHA2DS2-VASC. We also observed that the average accuracy 
for the main outcome classifier slightly increased, from 97.2% to 97.5% by reducing the 
number of variables from 18 to 8. 
 
Table 22: Evaluation of trained classifiers performances with ROC curve analysis.  
MH 
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Legend: MH= major hemorrhage; TEE= thromboembolic events. 
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4. Discussion 
 Pre-existing or new-onset AF are common in an ICU population. In this cohort, 
critically-ill patients coaffected by AF represented 19% of the sample in the same time-
period. This prevalence is slightly lower than the one reported in literature[5], however this 
observation could be due to the common effect of under-reporting of  this type of arrhythmia 
in ICU[79], which is described especially when adopting administrative databases and 
retrospective models. 
 MO was observed in 194 (13.6%) subjects of the sample: this group was significantly 
older and more often affected by ACS, CS, SS, ARF or infectious diseases, as shown in 
Table 5. TEE were diagnosed in 212 patients (14.8% of the sample). In this subpopulation, 
CHA2DS2-VASc score had a median of 4 [IQR:3]. According to the original validation 
cohort of CHA2DS2-VASc, a similar embolic risk could be observed only in patients with a 
CHA2DS2-VASc ³8[48]. The older age of the patients, the concomitant critical illnesses and 
comorbidities could at least partially explain the excess of TEE observed in this population. 
MH was present in 133 subjects (9.30% of the sample). In this group, HAS-BLED 
score had a median of 2 [IQR:1]. Data from the overall SPORTIF cohorts underlined that a 
similar risk of bleeding was present only in subjects HAS-BLED scores ³4[49]. In our 
cohort, 90.2% of MH were observed in patients with HAS-BLED <4. The excess in the 
haemorragic risk could be explained by several aspects: first, some critical illness, as severe 
sepsis or septic shock, especially when complicated by diffuse intravascular coagulation or 
atypical uremic-hemolytic syndromes, are often associated with platelet or coagulation 
abnormalities; second, patients with ACS are often treated with antiplatelet agents which 
could at least facilitate bleeding; third, the high prevalence of chronic or acute kidney 
dysfunction are recognized risk factors for MH, particularly among subjects undergoing 
parenteral anticoagulation.  
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Of note, both CHA2DS2-VASc and HAS-BLED showed a good negative predictive 
value, being able to exclude TEE and MH. CHA2DS2-VASc values <2 were associated to a 
NPV of 95.0% (87.6-98.1%) for TEE, while HAS-BLED scores <3 had a NPV of 91.3% 
(89.8-92.5%) for MH, as shown in Table 10. Thus, a possible role for the “classical” score 
systems in critically ill subjects could be of identifying clusters at “very low risk” of TEE and 
MH. However, this sample should be only used to suggest this hypothesis, since the number 
of “low-risk” patients is very scarce, due to advanced age, number of comorbidities and 
higher prevalence of cardiovascular diseases. This should not be interpreted as a selection 
bias, but as a clinical difference of the sICU population from the commonly studied cohorts. 
In fact, even adopting a less age- and vascular-dependent score, as CHADS2, we obtained 
results similar to the ones observed with CHA2DS2-VASc. 
These observations synthesize the difficulty of the emergency physician in managing 
anticoagulation in the elderly, critically-ill patients affected by AF: independently from the 
cause of admission, this group of subjects shows a very high risk of both cardioembolic and 
haemorragic events. Moreover, we observed in CHA2DS2-VASc and HAS-BLED a non-
significant difference in the distribution of the subjects according different results, which 
translated into a non-significant predictive capacity of each score, as shown in Table 10 and 
Figure 5. 
In this sample, the predictive performance of CHA2DS2-VASc score was non-
significant and showed a very low accuracy. The role of CHA2DS2-VASc score in predicting 
TEE in patients admitted to an ICU/sICU is still object of debate: only a single perspective 
cohort[38] study of patients found a moderately predictive value of this score, but suggested a 
different cut-off value in order to improve its performance. Other studies observed a very 
poor or non-significant prediction of the events[19,37] in this setting. The ability of 
CHA2DS2-VASc in stratifying patient’s thromboembolic risk during AF has been shown to 
be very low also in specific clinical settings, as AHF[80], ACS[36,39], sepsis[36,37] and 
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ARF[36]. This suggests that a correct risk stratification using this score could be performed 
in populations similar to the original validation cohort. Moreover, it is necessary to underline 
that, while pre-existing AF shares at least the same risk factors with primary AF observed in 
outpatients, being the critical illness a modifier of events, new-onset AF should be considered 
as a completely different entity, with different risk factors and a different cardioembolic and 
haemorragic risk profile[14].  
Similarly, HAS-BLED score was not able to predict accurately MH in this cohort, 
despite a significantly increased prevalence of serious bleeding and haemorragic shock. 
Literature regarding the evaluation of bleeding risk in critical illness is poor, and previously 
published studies underlined that this risk is not accurately evaluated by HAS-BLED 
score[36]. Moreover, HAS-BLED has not been validated in such populations.  
In the context of critically-ill patients with AF, we noted that, while both CHA2DS2-
VASc and HAS-BLED scores were not associated with the occurrence of TEE and MH and 
did not show any predictive ability for these events, these scores demonstrated the ability of 
identifying the patients with a very low risk, who less likely would experience the outcome.  
Moreover, in absence of more accurate and validated stratification tools, the latest 
European Heart Rhythm Association (EHRA) consensus document on the management of AF 
in critically-ill patients still suggests stratifying both thromboembolic and haemorragic risk 
with CHA2DS2-VASc and HAS-BLED[81] and to treat AF accordingly to the more recent 
ESC guidelines[1].  
However, a large study performed in a retrospective cohort of septic patients 
underlined that the high risk of bleeding in critically-ill patients receiving parenteral 
anticoagulation was not counterbalanced by a significant reduction of ischemic stroke 
rate[37].  A CHADS2-based anticoagulation strategy was also associated to an increased risk 
of bleeding in absence of a statistically significant increase in survival rate during the 
hospitalization in ICU[40]. Moreover, anticoagulation was not associated to a reduced in-
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hospital and long-term stroke risk in ACS, ARF and sepsis[36], but it was clearly associated 
to a significantly increased risk of bleeding.  
In a recently published work, we have already underlined the discrepancies between 
different guidelines in the topic of AF[82], which are mainly due to the absence of studies or 
to the poor quality of the studies adopted to elaborate specific indications. 
In this study, when stratifying our sample according to current guidelines adherence, 
we observed that a GL-adherent approach was significantly associated to an overall reduction 
of TEE (4,8%), but also correlated to a significantly increased risk of adverse events. 
Particularly, GL-adherent patients had the highest probability of both MH (13,2%) and MO 
(16,4%), as shown in Figure 6. When compared to GL-adherent patients, undertreated 
patients had significantly increased risk of TEE, a reduced risk of MH and a reduced risk of 
MO, as shown in Table 11. Overtreatment did not confer significantly to a further increased 
risk of TEE, MH or MO when compared to a GL-adherent approach. 
Moreover, we observed that warfarin use at the admission was associated to a two-
fold increased risk of death or ICU transfer when compared to no anticoagulant use, as shown 
in Table 8. LMWH use, however, did not confer an increased risk of MO, and antiplatelet 
drugs use was associated to a reduction of the risk of MO. 
In this sample, nor CHA2DS2-VASc nor HAS-BLED were able to predict events in 
critically-ill subjects. Moreover, the application of current ESC guidelines was effective in 
reducing TEE but was associated to an increased risk of both MO and MH. To date, 
according to our data and current literature, both risk stratification of ischemic and 
haemorragic risk and medical management of AF in critically-ill patients still represent a 
“gray zone” of evidence.  
As in this case, ICU represents an especially compelling case for clinical data 
analysis: the value of many treatments and interventions is still unproven, and high-quality 
data supporting or discouraging specific practices are embarrassingly sparse[83,84]. 
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Guidelines developed to standardize practice are dependent on an evidence base that is 
surprisingly thin considering the copious data generated in ICU. Big data analysis and ML 
represent a new and promising technologies which are deemed to be highly efficient in 
exploring patterns and hidden relationships between clinical variables[41], allowing to 
develop more specific clinical prediction tools and open the road to personalized medicine, 
especially in ICU/sICU where large volumes of data are readily available.  
Predictive models adopting these new technologies have already outperformed their 
gold standard in several acute pathologies, as AKI[85] or PE[44]. With this study, we applied 
these new techniques in the clinical setting critically-ill patients affected by AF, aiming to 
highlight the most relevant features associated to the most important adverse events, that are 
death or ICU transfer, major bleeding and cardioembolism. We then engineered new 
predictive scores to improve the prediction of AF-related events.  
The strongest association with major haemorragic events was observed with age, 
specific critical illnesses (AHF, ARF, SYN), specific chronic conditions (CKD, AC and CA), 
anticoagulant and antiplatelet therapy, procedures performed in sICU (CVE), labile TTR and 
a history of previous gastrointestinal bleeding. Some of these factors (age, antiplatelet drugs 
use, CKD, labile TTR and previous gastrointestinal bleeding) have already been identified 
and included in the HAS-BLED score[86]. Other factors (AC and CA) are recognized by 
literature as risk factors for MH, and have already been considered in other risk scores, as 
HEMORR2HAGES[87]. Some items, however (AHF, ARF, SYN), are specific for the 
critically-ill patient. Adopting this 9-item score with a TDA-based computation, we obtained 
a significant increase in the accuracy of prediction of MH [AUC from 0.52 to 0.90, p<0.001], 
as shown in Table 20, Table 21 and Table 22. 
The association with TEE was robust for age, sex, specific critical illnesses (AHF, 
ACS, SYN), procedures performed in sICU (CVE, CVF), AF type, specific chronic 
conditions (CHF, COPD, mitral and aortic valve pathologies), the anticoagulant strategy, the 
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time in therapeutic range and a previous stroke/TIA. Some of these factors are already 
considered in CHA2DS2-VASc score (CHF, age, sex and previous stroke/TIA). Other 
features, as anticoagulant therapy, time in therapeutic range, CVE and CVF are directly 
related to the acute management of the arrhythmia. Last, some items (AHF, ACS, SYN) refer 
directly to the critical pathology which caused the sICU admission. Thus, we engineered a 
TDA-based model which allowed a significant increase in the prediction of TEE [AUC from 
0.493 to 0.82, p<0.001], as shown in Table 20, Table 21 and Table 22. 
While HAS-BLED and CHA2DS2-VASc are still not validated for ICU, intensive-care 
physicians already have several validated tools to predict in-hospital mortality among 
critically-ill patients, as SAPS-II[88] and APACHE-II[89] scores which are able to predict 
the outcome with an area under the ROC curve greater than 80%[90]. Some predictors of MO 
extracted from our population were similar to the items considered in both scores, as age, 
COPD, ARF and shock. Other items were already associated in previous studies to a worse 
outcome in this clinical setting[91–93]. However, it is interesting to underline that, in a 
selected population of critically-ill patients affected by AF, we were able to identify AF-
specific items, as anticoagulant strategy, antiplatelet drugs use, CVE, TEE, MH and HS, as 
strong determinants of in-hospital death or ICU transfer.  
This last observation underlines also the importance of AF-related events in the 
determination of major outcomes of the critically-ill patient. The absence of robust evidence 
both in risk stratification and in the consequent anticoagulant strategy poses the critically-ill 
patient affected by AF at risk of adverse events even if treated according the current 
guidelines. This preliminary work underlines the urgent need of specific trials for the 
management of new-onset or pre-existing AF in critically-illness.  
Study limitations 
This is a single-center, retrospective study, thus generalizability of results is limited 
and require further confirmations with larger, multicentric and prospective studies. The 
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peculiar TDA-based approach adopted for feature selection and event prediction of events is 
robust but experimental and, despite the encouraging results, it will require further 
validations: in particular, a larger prospective validation cohort is necessary to confirm our 
preliminary results. The validation cohort should enroll particularly patients treated 
accordingly to ESC 2016 guidelines. Last, this retrospective cohort considered subjects 
treated with warfarin or LMWH but did not involve patients treated with direct oral 
anticoagulants: these drugs have been introduced later and seem to have a safer bleeding 
profile: future studies will have to consider also this new class of medications in this specific 
setting of patients. 
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